← Leaderboards
Ke Xu
Yale University
$9,636,315
Attributed
$14,222,503
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,222,503 · 9
By mechanism
R01$13,320,877 · 6
R21$340,912 · 1
P60$300,223 · 1
R03$260,491 · 1
Top collaborators
- Bradley E Aouizerat12 shared
- Rajita Sinha2 shared
Most similar at Yale University
Same institution · by research overlap
- Gail D'onofrio$17,031,011
- Trace S Kershaw$22,243,386
- Jaimie Meyer$7,115,526
- Nathan B Hansen$7,849,116
- Nadia Abdala$3,279,480
Others in their field
Top investigators on “Cohort”
- David R. Weir · University Of Michigan At Ann Arbor$406,814,098
- George R Seage · Abt Associates, Inc.$297,656,361
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$242,146,554
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
- Lawrence Corey · Fred Hutchinson Cancer Center$227,738,417
- James Dennis Neaton · Northwestern University$203,539,316
Research focus
CohortGenesGene ExpressionEpigenetic ProcessDna MethylationHiv InfectionsSamplingCohort StudiesPharmaceutical PreparationsMethylomeEpigenomicsAgingComorbidityLinkVeteransImmune FunctionImmuneCell TypeMortalityBiological MarkersBiologicalTranscriptome SequencingInflammatoryGenotype
Grant awards (28)
Cell-type based epigenomic analysis to identify druggable genes for people living with HIV infection and using cannabis$999,317
R01 · FY2025 · DA · contact PI
Stress-immune mechanisms for people living with HIV, CUD and Depression$895,523
R01 · FY2025 · DA · contact PI
In vivo study of THC-induced immunogenome changes at single cell resolution in HIV-infected humans$484,959
R01 · FY2025 · DA · contact PI
AWARE Project 1: Impact of unhealthy alcohol use, HIV reservoirs, and social disadvantage on candidate biomarkers of inflammaging$300,223
P60 · FY2025 · AA · contact PI
Cell-type based epigenomic analysis to identify druggable genes for people living with HIV infection and using cannabis$1,032,192
R01 · FY2024 · DA · contact PI
Stress-immune mechanisms for people living with HIV, CUD and Depression$895,093
R01 · FY2024 · DA · contact PI
In vivo study of THC-induced immunogenome changes at single cell resolution in HIV-infected humans$491,556
R01 · FY2023 · DA · contact PI
Feature selection of DNA methylation biosignatures for neuropathy with comorbid drug abuse in the setting of HIV infection$561,829
R01 · FY2022 · DA · contact PI
In vivo study of THC-induced immunogenome changes at single cell resolution in HIV-infected humans$511,727
R01 · FY2022 · DA · contact PI
Defining the impact of injection drug use on antiretroviral therapy and HIV treatment outcomes: an (epi)genomic approach$379,063
R01 · FY2022 · DA · contact PI
Feature selection of DNA methylation biosignatures for neuropathy with comorbid drug abuse in the setting of HIV infection$570,656
R01 · FY2021 · DA · contact PI
In vivo study of THC-induced immunogenome changes at single cell resolution in HIV-infected humans$522,410
R01 · FY2021 · DA · contact PI
Defining the impact of injection drug use on antiretroviral therapy and HIV treatment outcomes: an (epi)genomic approach$363,122
R01 · FY2021 · DA · contact PI
Feature selection of DNA methylation biosignatures for neuropathy with comorbid drug abuse in the setting of HIV infection$595,425
R01 · FY2020 · DA · contact PI
In vivo study of THC-induced immunogenome changes at single cell resolution in HIV-infected humans$531,844
R01 · FY2020 · DA · contact PI
Defining the impact of injection drug use on antiretroviral therapy and HIV treatment outcomes: an (epi)genomic approach$517,732
R01 · FY2020 · DA · contact PI
Feature selection of DNA methylation biosignatures for neuropathy with comorbid drug abuse in the setting of HIV infection$599,984
R01 · FY2019 · DA · contact PI
Defining the impact of injection drug use on antiretroviral therapy and HIV treatment outcomes: an (epi)genomic approach$592,854
R01 · FY2019 · DA · contact PI
Methylome-wide and mQTL analysis of HIV progression in the context of cocaine use$365,570
R01 · FY2019 · DA · contact PI
Feature selection of DNA methylation biosignatures for neuropathy with comorbid drug abuse in the setting of HIV infection$606,847
R01 · FY2018 · DA · contact PI
Defining the impact of injection drug use on antiretroviral therapy and HIV treatment outcomes: an (epi)genomic approach$562,739
R01 · FY2018 · DA · contact PI
Methylome-wide and mQTL analysis of HIV progression in the context of cocaine use$400,630
R01 · FY2018 · DA · contact PI
Methylome-wide and mQTL analysis of HIV progression in the context of cocaine use$371,252
R01 · FY2017 · DA · contact PI
Methylome-wide and mQTL analysis of HIV progression in the context of cocaine use$468,553
R01 · FY2016 · DA · contact PI
Genome-wide DNA methylation in HIV infected drug users$129,591
R03 · FY2016 · DA · contact PI
Genome-wide DNA methylation in HIV infected drug users$130,900
R03 · FY2015 · DA · contact PI
Longitudinal exome-focused GWAS for alcohol use in a cohort with and without HIV$87,293
R21 · FY2015 · AA · contact PI
Longitudinal exome-focused GWAS for alcohol use in a cohort with and without HIV$253,619
R21 · FY2014 · AA · contact PI